1. Home
  2. KDLY vs BCDA Comparison

KDLY vs BCDA Comparison

Compare KDLY & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KDLY
  • BCDA
  • Stock Information
  • Founded
  • KDLY 2019
  • BCDA N/A
  • Country
  • KDLY United States
  • BCDA United States
  • Employees
  • KDLY N/A
  • BCDA N/A
  • Industry
  • KDLY
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • KDLY
  • BCDA Health Care
  • Exchange
  • KDLY NYSE
  • BCDA Nasdaq
  • Market Cap
  • KDLY 7.8M
  • BCDA 7.9M
  • IPO Year
  • KDLY 2024
  • BCDA N/A
  • Fundamental
  • Price
  • KDLY $3.28
  • BCDA $2.63
  • Analyst Decision
  • KDLY
  • BCDA Strong Buy
  • Analyst Count
  • KDLY 0
  • BCDA 1
  • Target Price
  • KDLY N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • KDLY 810.1K
  • BCDA 55.0K
  • Earning Date
  • KDLY 02-18-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • KDLY N/A
  • BCDA N/A
  • EPS Growth
  • KDLY N/A
  • BCDA N/A
  • EPS
  • KDLY N/A
  • BCDA N/A
  • Revenue
  • KDLY $2,875,400.00
  • BCDA $71,000.00
  • Revenue This Year
  • KDLY N/A
  • BCDA N/A
  • Revenue Next Year
  • KDLY N/A
  • BCDA N/A
  • P/E Ratio
  • KDLY N/A
  • BCDA N/A
  • Revenue Growth
  • KDLY N/A
  • BCDA N/A
  • 52 Week Low
  • KDLY $0.65
  • BCDA $1.63
  • 52 Week High
  • KDLY $5.25
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • KDLY N/A
  • BCDA 61.81
  • Support Level
  • KDLY N/A
  • BCDA $2.27
  • Resistance Level
  • KDLY N/A
  • BCDA $2.78
  • Average True Range (ATR)
  • KDLY 0.00
  • BCDA 0.27
  • MACD
  • KDLY 0.00
  • BCDA 0.02
  • Stochastic Oscillator
  • KDLY 0.00
  • BCDA 77.61

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: